Related Experiment Videos
Long-term evaluation of indobufen in peripheral vascular disease
1Laboratorio di Microcircolazione Cardiovascular Institute Università Abruzzese G.D' Annunzio, Chieti, Italy.
Insights
Indobufen effectively improved walking distance in peripheral vascular disease patients. This platelet aggregation inhibitor demonstrated superior safety and efficacy compared to aspirin, with reduced side effects and cardiac events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Vascular Surgery
Background:
- Peripheral vascular disease (PVD) and intermittent claudication significantly impair quality of life.
- Platelet aggregation inhibitors are crucial in managing vascular conditions.
- Optimizing treatment for intermittent claudication requires evaluating drug efficacy and safety.
Purpose of the Study:
- To evaluate the efficacy and safety of Indobufen compared to aspirin and placebo in patients with intermittent claudication.
- To assess the impact of Indobufen on pain-free walking distance (PFWD) and global walking distance (GWD).
- To determine the long-term effects and tolerability of Indobufen in chronic peripheral vascular disease management.
Main Methods:
- A prospective study involving 306 patients with intermittent claudication due to PVD.
- Patients were randomized to receive Indobufen, aspirin (ASA), or no treatment (control).
- Treadmill exercise testing was used to measure PFWD, GWD, and recovery time over a one-year follow-up period.
Main Results:
- Indobufen significantly improved PFWD and GWD in all patient groups compared to ASA and placebo.
- Fewer adverse events were reported with Indobufen treatment.
- Indobufen treatment was associated with reduced cardiac morbidity and mortality.
Conclusions:
- Indobufen is a safe and effective treatment for chronic peripheral vascular disease, improving walking capacity.
- Indobufen offers advantages over aspirin in terms of efficacy and safety profile.
- Long-term Indobufen therapy appears well-tolerated and beneficial for patients with intermittent claudication.
Abstract:
Indobufen--an inhibitor of platelets aggregation--has been used in 306 patients with intermittent claudication due to peripheral vascular disease. Patients were treated and followed up for one year. One patient of every 3 treated with indobufen was treated with ASA, and a control group of patients receiving no treatment was also followed up. The authors studied by means of a treadmill exercise test the pain-free walking distance (PFWD), the global walking distance (GWD), and the recovery time after exercise. The treatment period was completed by 290 patients: 204 claudicants, 51 claudicants with diabetes, and 35 with a short PFWD and GWD (greater than 150 m). Indobufen was more effective than ASA in improving the PFWD and GWD in all groups. There were also fewer side effects with indobufen, and cardiac morbidity and mortality was also reduced. In conclusion indobufen showed its activity and safety in chronic treatment of patients with peripheral disease, and we suggest that it may be used for long periods without side effects.